adagrasib
mirati
['sclc', 'krystal-1', 'adagrasib', 'nsclc', 'krystal,1']
 #asco22 showed from the krystal-1 trial that adagrasib in patients with #kras g12cm #nsclc with untreated cns mets had intracranial orr=32%, dcr =84%, and systemic orr =37%. small patient population.
Dir. STEM Workforce Initiatives @LUNGevity. #BME, #Cancer, #Genomics, Dig. #Pathology, jujitsu, and outreach. Thoughts are my own. RT or follow != endorsement.